Adis Journals
Browse

Patient Preference for Subcutaneous Versus Intravenous Administration With Every 6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Download (879.02 kB)
Version 2 2024-07-25, 08:05
Version 1 2024-07-16, 15:06
media
posted on 2024-07-25, 08:05 authored by Adis Journals on behalf of:, Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky



 The above infographic represents the opinions of the authors.  For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). 

History

Usage metrics

    Neurology and Therapy

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC